1186P Impact of temozolomide (TEM) and capecitabine (CAP) dose reductions in toxicity and efficacy in patients (pts) with neuroendocrine neoplasms (NENs) treated with CAPTEM chemotherapy

Autor:	Hernando, J., Garcia-Alvarez, A., Castaneda, D.H. Marmolejo, Eyzaguirre, D.A. Acosta, Garcia, M. Diez, Gonzalez, N. Saoudi, Casteras, A., Simo, M., Burillo, A. Garcia, Merino, X., Blanco, L., Sanchez, J.L., Roca, M., Capdevila, J.
Zdroj:	In Annals of Oncology September 2020 31 Supplement 4:S782-S782
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu